ALK and non-small cell lung carcinoma: Crizotinib was the first FDA‐approved ALKi for NSCLC patients.45 However, most patients develop drug resistance after approximately 10.5 months of crizotinib treatment.7 This acquired drug resistance prompted the development of second‐ and third‐generation ALK inhibitors.